These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 33315691)
1. Predictors of clinical improvement with sacubitril/valsartan in a real world population with chronic heart failure. Correale M; Tricarico L; Ferraretti A; Formica ES; Padovano G; Monaco I; Merolla G; Tozzi V; Di Biase M; Iacoviello M; Brunetti ND J Cardiovasc Med (Hagerstown); 2021 Jun; 22(6):508-510. PubMed ID: 33315691 [No Abstract] [Full Text] [Related]
2. Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population. Hu J; Wu Y; Zhou X; Wang X; Jiang W; Huo J; Shan Q J Cardiovasc Pharmacol; 2020 Oct; 76(4):445-451. PubMed ID: 33030857 [TBL] [Abstract][Full Text] [Related]
3. Sacubitril/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study. Dos Santos MR; Alves MNN; Jordão CP; Pinto CEN; Correa KTS; de Souza FR; da Fonseca GWP; Tomaz Filho J; Costa M; Pereira RMR; Negrão CE; Barretto ACP Am Heart J; 2021 Sep; 239():1-10. PubMed ID: 33992607 [TBL] [Abstract][Full Text] [Related]
4. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP; N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794 [TBL] [Abstract][Full Text] [Related]
5. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398 [TBL] [Abstract][Full Text] [Related]
9. Benefits of early administration of Sacubitril/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. Zhang Y; Wu Y; Zhang K; Ke Z; Hu P; Jin D Coron Artery Dis; 2021 Aug; 32(5):427-431. PubMed ID: 32868662 [TBL] [Abstract][Full Text] [Related]
10. Sacubitril-Valsartan and Heart Function in End-stage Kidney Disease. Slomski A JAMA; 2022 Oct; 328(16):1582. PubMed ID: 36282257 [No Abstract] [Full Text] [Related]
11. In brief: Sacubitril/valsartan (Entresto) expanded indication. Med Lett Drugs Ther; 2021 May; 63(1623):65. PubMed ID: 33976096 [No Abstract] [Full Text] [Related]
12. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. Ehteshami-Afshar S; Mooney L; Dewan P; Desai AS; Lang NN; Lefkowitz MP; Petrie MC; Rizkala AR; Rouleau JL; Solomon SD; Swedberg K; Shi VC; Zile MR; Packer M; McMurray JJV; Jhund PS; Hawkins NM J Am Heart Assoc; 2021 Feb; 10(4):e019238. PubMed ID: 33522249 [TBL] [Abstract][Full Text] [Related]
13. Renal protective effect of sacubitril/valsartan in patients with heart failure. Hsieh HL; Chen CY; Chen CH; Hsu SC; Huang WC; Sue YM; Lin FY; Shih CM; Chang YC; Huang PH; Liu CT Sci Rep; 2021 Feb; 11(1):4593. PubMed ID: 33633282 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936 [TBL] [Abstract][Full Text] [Related]
15. Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis. Kim H; Oh J; Lee S; Ha J; Yoon M; Chun KH; Lee CJ; Park S; Lee SH; Kang SM Sci Rep; 2021 Aug; 11(1):16335. PubMed ID: 34381126 [TBL] [Abstract][Full Text] [Related]
17. Sacubitril/Valsartan in the Management of Heart Failure Patients with Cardiac Implantable Electronic Devices. Cheng S; Zhang N; Hua W Am J Cardiovasc Drugs; 2021 Jul; 21(4):383-393. PubMed ID: 33118151 [TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of transient worsening renal function after initiation of sacubitril/valsartan. Masarone D; Melillo E; Errigo V; Valente F; Pacileo G Curr Med Res Opin; 2021 Jan; 37(1):9-12. PubMed ID: 33210952 [TBL] [Abstract][Full Text] [Related]
19. Effects of sacubitril/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction. Wang H; Fu X Coron Artery Dis; 2021 Aug; 32(5):418-426. PubMed ID: 32732515 [TBL] [Abstract][Full Text] [Related]
20. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan. Liu RC Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]